Trials / Completed
CompletedNCT07196280
Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10,000 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5-Alpha Reductase Inhibitors | Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2025-09-29
- Last updated
- 2025-09-29
Source: ClinicalTrials.gov record NCT07196280. Inclusion in this directory is not an endorsement.